-
Je něco špatně v tomto záznamu ?
Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia
J. Ruda-Kucerova, Z. Babinska, T. Stark, V. Micale,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- analýza rozptylu MeSH
- autoaplikace MeSH
- ketamin farmakologie toxicita MeSH
- krysa rodu rattus MeSH
- lokomoce účinky léků MeSH
- methamfetamin aplikace a dávkování MeSH
- methylazoxymethanolacetát analogy a deriváty toxicita MeSH
- modely nemocí na zvířatech MeSH
- operantní podmiňování účinky léků MeSH
- potkani Sprague-Dawley MeSH
- schizofrenie chemicky indukované farmakoterapie MeSH
- stimulanty centrálního nervového systému aplikace a dávkování MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of ketamine on drug addiction in schizophrenia using the methylazoxymethanol (MAM) acetate rat model on operant IV methamphetamine (METH) self-administration. MAM was administered intraperitoneally (22 mg/kg) on gestational day 17. Locomotor activity test and later IV self-administration (IVSA) were then performed in the male offspring followed by a period of forced abstinence and relapse of METH taking. After reaching stable intakes in the relapse phase, ketamine (5 mg/kg) was administered intraperitoneally 30 min prior to the self-administration session. As documented previously, the MAM rats showed a lack of habituation in the locomotor activity test but developed stable maintenance of METH self-administration with no difference in operant behaviour to control animals. Results show that ketamine treatment significantly reduced the METH intake in the control animals but not in MAM animals. Ketamine effect on METH self-administration may be explained by increased glutamatergic signalling in the prefrontal cortex caused by the N-methyl-D-aspartate antagonism and disinhibition of GABA interneurons which was shown to be impaired in the MAM rats. This mechanism may at least partly explain the clinically proven anti-craving potential of ketamine and allow development of more specific anti-craving medications with fewer risks.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010667
- 003
- CZ-PrNML
- 005
- 20180418105029.0
- 007
- ta
- 008
- 180404s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12640-017-9718-9 $2 doi
- 035 __
- $a (PubMed)28421529
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. jkucer@med.muni.cz.
- 245 10
- $a Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia / $c J. Ruda-Kucerova, Z. Babinska, T. Stark, V. Micale,
- 520 9_
- $a Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of ketamine on drug addiction in schizophrenia using the methylazoxymethanol (MAM) acetate rat model on operant IV methamphetamine (METH) self-administration. MAM was administered intraperitoneally (22 mg/kg) on gestational day 17. Locomotor activity test and later IV self-administration (IVSA) were then performed in the male offspring followed by a period of forced abstinence and relapse of METH taking. After reaching stable intakes in the relapse phase, ketamine (5 mg/kg) was administered intraperitoneally 30 min prior to the self-administration session. As documented previously, the MAM rats showed a lack of habituation in the locomotor activity test but developed stable maintenance of METH self-administration with no difference in operant behaviour to control animals. Results show that ketamine treatment significantly reduced the METH intake in the control animals but not in MAM animals. Ketamine effect on METH self-administration may be explained by increased glutamatergic signalling in the prefrontal cortex caused by the N-methyl-D-aspartate antagonism and disinhibition of GABA interneurons which was shown to be impaired in the MAM rats. This mechanism may at least partly explain the clinically proven anti-craving potential of ketamine and allow development of more specific anti-craving medications with fewer risks.
- 650 _2
- $a analýza rozptylu $7 D000704
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a stimulanty centrálního nervového systému $x aplikace a dávkování $7 D000697
- 650 _2
- $a operantní podmiňování $x účinky léků $7 D003216
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a ketamin $x farmakologie $x toxicita $7 D007649
- 650 _2
- $a lokomoce $x účinky léků $7 D008124
- 650 _2
- $a methamfetamin $x aplikace a dávkování $7 D008694
- 650 _2
- $a methylazoxymethanolacetát $x analogy a deriváty $x toxicita $7 D008746
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a schizofrenie $x chemicky indukované $x farmakoterapie $7 D012559
- 650 _2
- $a autoaplikace $7 D012646
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Babinska, Zuzana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Stark, Tibor $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Micale, Vincenzo $u CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy.
- 773 0_
- $w MED00180457 $t Neurotoxicity research $x 1476-3524 $g Roč. 32, č. 1 (2017), s. 121-133
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28421529 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180418105129 $b ABA008
- 999 __
- $a ok $b bmc $g 1288152 $s 1007479
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 32 $c 1 $d 121-133 $e 20170418 $i 1476-3524 $m Neurotoxicity research $n Neurotox Res $x MED00180457
- LZP __
- $a Pubmed-20180404